Literature DB >> 35034099

Associations among locus coeruleus catecholamines, tau pathology, and memory in aging.

Claire J Ciampa1, Jourdan H Parent1, Theresa M Harrison2, Rebekah M Fain1, Matthew J Betts3,4,5, Anne Maass4, Joseph R Winer2, Suzanne L Baker6, Mustafa Janabi6, Daniella J Furman2,7, Mark D'Esposito2, William J Jagust2,6, Anne S Berry8,9.   

Abstract

The locus coeruleus (LC) is the brain's major source of the neuromodulator norepinephrine, and is also profoundly vulnerable to the development of Alzheimer's disease (AD)-related tau pathology. Norepinephrine plays a role in neuroprotective functions that may reduce AD progression, and also underlies optimal memory performance. Successful maintenance of LC neurochemical function represents a candidate mechanism of protection against the propagation of AD-related pathology and may facilitate the preservation of memory performance despite pathology. Using [18F]Fluoro-m-tyrosine ([18F]FMT) PET imaging to measure catecholamine synthesis capacity in LC regions of interest, we examined relationships among LC neurochemical function, AD-related pathology, and memory performance in cognitively normal older adults (n = 49). Participants underwent [11C]Pittsburgh compound B and [18F]Flortaucipir PET to quantify β-amyloid (n = 49) and tau burden (n = 42) respectively. In individuals with substantial β-amyloid, higher LC [18F]FMT net tracer influx (Kivis) was associated with lower temporal tau. Longitudinal tau-PET analyses in a subset of our sample (n = 30) support these findings to reveal reduced temporal tau accumulation in the context of higher LC [18F]FMT Kivis. Higher LC catecholamine synthesis capacity was positively correlated with self-reported cognitive engagement and physical activity across the lifespan, established predictors of successful aging measured with the Lifetime Experiences Questionnaire. LC catecholamine synthesis capacity moderated tau's negative effect on memory, such that higher LC catecholamine synthesis capacity was associated with better-than-expected memory performance given an individual's tau burden. These PET findings provide insight into the neurochemical mechanisms of AD vulnerability and cognitive resilience in the living human brain.
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35034099      PMCID: PMC8938463          DOI: 10.1038/s41386-022-01269-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  62 in total

Review 1.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction.

Authors:  Y I Sheline; K Miller; M E Bardgett; J G Csernansky
Journal:  Am J Geriatr Psychiatry       Date:  1998       Impact factor: 4.105

3.  Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease.

Authors:  B A Lawlor; L M Bierer; T M Ryan; J Schmeidler; P J Knott; L L Williams; R C Mohs; K L Davis
Journal:  Biol Psychiatry       Date:  1995-08-01       Impact factor: 13.382

4.  Neuromelanin marks the spot: identifying a locus coeruleus biomarker of cognitive reserve in healthy aging.

Authors:  David V Clewett; Tae-Ho Lee; Steven Greening; Allison Ponzio; Eshed Margalit; Mara Mather
Journal:  Neurobiol Aging       Date:  2015-10-29       Impact factor: 4.673

5.  Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus.

Authors:  Seong Su Kang; Xia Liu; Eun Hee Ahn; Jie Xiang; Fredric P Manfredsson; Xifei Yang; Hongbo R Luo; L Cameron Liles; David Weinshenker; Keqiang Ye
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

6.  Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.

Authors:  Heidi I L Jacobs; Joost M Riphagen; Inez H G B Ramakers; Frans R J Verhey
Journal:  Mol Psychiatry       Date:  2019-05-28       Impact factor: 15.992

Review 7.  Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.

Authors:  Matthew J Betts; Evgeniya Kirilina; Maria C G Otaduy; Dimo Ivanov; Julio Acosta-Cabronero; Martina F Callaghan; Christian Lambert; Arturo Cardenas-Blanco; Kerrin Pine; Luca Passamonti; Clare Loane; Max C Keuken; Paula Trujillo; Falk Lüsebrink; Hendrik Mattern; Kathy Y Liu; Nikos Priovoulos; Klaus Fliessbach; Martin J Dahl; Anne Maaß; Christopher F Madelung; David Meder; Alexander J Ehrenberg; Oliver Speck; Nikolaus Weiskopf; Raymond Dolan; Ben Inglis; Duygu Tosun; Markus Morawski; Fabio A Zucca; Hartwig R Siebner; Mara Mather; Kamil Uludag; Helmut Heinsen; Benedikt A Poser; Robert Howard; Luigi Zecca; James B Rowe; Lea T Grinberg; Heidi I L Jacobs; Emrah Düzel; Dorothea Hämmerer
Journal:  Brain       Date:  2019-09-01       Impact factor: 13.501

8.  Locus coeruleus MRI contrast is associated with cortical thickness in older adults.

Authors:  Shelby L Bachman; Martin J Dahl; Markus Werkle-Bergner; Sandra Düzel; Caroline Garcia Forlim; Ulman Lindenberger; Simone Kühn; Mara Mather
Journal:  Neurobiol Aging       Date:  2020-12-29       Impact factor: 4.673

9.  Elevated Norepinephrine Metabolism Gauges Alzheimer's Disease-Related Pathology and Memory Decline.

Authors:  Joost M Riphagen; Maxime van Egroo; Heidi I L Jacobs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

10.  Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences.

Authors:  Robert Howard; Dorothea Hämmerer; Kathy Y Liu; Rogier A Kievit; Kamen A Tsvetanov; Matthew J Betts; Emrah Düzel; James B Rowe
Journal:  Nat Commun       Date:  2020-04-06       Impact factor: 14.919

View more
  1 in total

Review 1.  Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target.

Authors:  Irene L Gutiérrez; Cinzia Dello Russo; Fabiana Novellino; Javier R Caso; Borja García-Bueno; Juan C Leza; José L M Madrigal
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.